Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenovirus serotype 26-expressing HPV18 vaccine JNJ-63682931

A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Ad26-expressing HPV18 vaccine JNJ-63682931
Ad26.HPV18 JNJ-63682931
adenovirus serotype 26-human papillomavirus 18 JNJ-63682931
monovalent HPV18 Ad26-vectored vaccine JNJ-63682931
Code name:JNJ 63682931
JNJ-63682931
JNJ63682931
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search